[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"essential-primary-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:essential-primary-hypertension":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645112","evaluating-the-effects-of-a-mindfulness-intervention-on-health-outcomes-in-individuals-with-hypertension-100645112",false,"NCT07679984","Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension","Inclusion Criteria:\n\n1. Age \\>18 years old.\n2. Established patient at OSU Family Medicine\n3. Diagnosis of primary essential hypertension\n4. Ability and willingness to participate in all Mindfulness in Motion (MIM) study activities.\n5. Ability and willingness to download MyCap, the smartphone app that securely links participant study responses to the REDCap study project.\n6. WiFi connectivity or LTE to allow use of MIM smartphone app and MyCap when not at OSU clinical site.\n\nExclusion Criteria:\n\n1. Inability to read and\u002For understand English (MIM intervention, study consent and questionnaires in English).\n2. Established mindfulness practice.\n3. Diagnosis of secondary hypertension with identifiable underlying causes including:\n\n   * Chronic kidney disease\n   * Renal artery stenosis\n   * Primary aldosteronism\n   * Cushing's syndrome\n   * Pheochromocytoma\n   * Obstructive sleep apnea\n   * Medication induced hypertension (e.g., steroids, NSAIDs)\n   * Pregnancy related hypertension\n4. Current severe alcohol or substance abuse disorder.\n5. Participants with documented cognitive disorder that limits the ability to independently participate in MIM program, read, understand, and\u002For complete the surveys; i.e. dementia, Alzheimer's or biological tests.\n6. Participants with major psychiatric disorders not controlled by medication or other psychiatric treatments.","ALL","18 Years",{"count":18,"type":19},140,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this study is to evaluate the effectiveness of adding the Mindfulness in Motion (MIM) program to the usual primary care for people with high blood pressure. MIM is a facilitated, 8-week online program that teaches simple ways to manage stress using mindfulness practices. The program also includes the use of a companion smartphone app throughout the 12-month study period. In this study, we will compare people who receive their usual care and take part in the MIM program with those who receive usual care alone to see if it helps improve blood pressure, weight, stress, sleep, and overall well-being. Over 12 months, all participants will be asked to complete short questionnaires about stress, sleep, and resilience four times via a smartphone, tablet, or computer.",[25,26],"Hypertension","Essential (Primary) Hypertension",[28,29,30,31,32,33,34],"hypertension","primary care","mindfulness","stress","resilience","sleep","blood pressure","NOT_YET_RECRUITING","2026-06-26",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":19},"2026-10-01",{"date":43,"type":19},"2028-05-01",{"name":45,"class":46},"Ohio State University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100640759","phase-4-effect-of-the-traditional-chinese-medicine-yufeng-ningxin-in-patients-with-hypertension-100640759","NCT07607275","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Male and female participants aged 18-65 years;\n2. Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications;\n3. The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written informed consent.\n\nExclusion Criteria:\n\n1. Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea);\n2. Orthostatic hypotension (symptomatic or asymptomatic);\n3. Participation in another hypertension-related clinical trial at enrollment or within 6 months prior;\n4. Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, glucocorticoids (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.);\n5. Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted;\n6. Severe hepatic or renal diseases (ALT \\>3 times the upper limit of normal value, or end stage renal disease on dialysis, or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2);\n7. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c\\>9.0%);\n8. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \\[TIA\\]);\n9. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;\n10. Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement;\n11. NYHA class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months;\n12. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;\n13. Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;\n14. Other severe diseases that may affect participant enrollment or survival, such as malignancy or acquired immunodeficiency syndrome (AIDS);\n15. Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing informed consent;\n16. Participants preparing for or under pregnancy and\u002For lactation;\n17. Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM);\n18. Other conditions deemed inappropriate for participation by the investigators.","65 Years",{"count":57,"type":19},350,[59],"PHASE4","Yufeng Ningxin, a traditional Chinese medicine, has demonstrated potential antihypertensive effects in animal studies and small clinical trials, but has not yet been rigorously evaluated in large randomized clinical trials. Here, the investigators conducted a double-blind, randomized controlled trial to assess the efficacy and safety of Yufeng Ningxin tablets in patients with hypertension.",[25,26],"RECRUITING","2026-05-29",{"date":65,"type":39},"2026-06-02",{"date":67,"type":19},"2026-05-15",{"date":69,"type":19},"2028-06-01",{"name":71,"class":46},"Beijing Anzhen Hospital",16,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":84,"briefSummary":85,"conditions":86,"keywords":94,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":47},"100622407","effect-of-electrical-stimulation-and-exercise-on-blood-flow-in-patients-with-resistant-high-blood-pressure-100622407","NCT07383220","Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure","Effect of Combined Transcutaneous Electrical Stimulation and Isometric Exercise on Peripheral Hemodynamic Parameters in Patients With Resistant Hypertension","Inclusion Criteria:\n\n* Age between 50 and 60 years. Both sexes were included Patients had been diagnosed with hypertension for at least 5 years.\n\nPatients had resistant hypertension according to (Whelton et al 2018), defined as:\n\n* Systolic blood pressure (SBP) ≥140 mmHg and\u002For diastolic blood pressure (DBP) ≥90 mmHg despite the use of three or more antihypertensive medications of different classes, including a diuretic,\n* or controlled blood pressure (\\\u003C140\u002F90 mmHg) while on four or more antihypertensive medications.\n\nBody Mass Index (BMI) 25: 34.9 kg\u002Fm²\n\nIncreased waist circumference, defined as:\n\n* Greater than 102 cm for males.\n* Greater than 88 cm for females.\n\nExclusion Criteria:\n\n* Secondary hypertension due to identifiable causes (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma).\n* History of major cardiovascular events in the last 6 months (e.g., myocardial infarction, stroke, or heart failure exacerbation).\n* Severe musculoskeletal or neurological disorders that impair the ability to perform isometric exercise safely (e.g., recent joint replacement, severe osteoarthritis, stroke with residual motor deficit).\n* Contraindications to the use of Transcutaneous Electrical Nerve Stimulation (TENS):\n\nImplanted electronic devices: pacemakers, cardioverter defibrillators. Uncontrolled arrhythmias. Sever skin condition: open wounds, rashes, burns, eczema. Peripheral neuropathy or sensory loss.\n\n-Known cognitive impairment or psychiatric conditions that would limit the ability to follow instructions or provide informed consent.","50 Years","60 Years",{"count":83,"type":19},50,[22],"The goal of this clinical trial is to learn if the combination between transcutaneous electrical nerve stimulation (TENS) and isometric exercise (IE) can improve blood pressure in men and women between 50 to 60 years old suffered from resistant hypertension which is a type of hypertension where blood pressure remains above your target goal despite the use of three or more different classes of antihypertensive medications at their maximum tolerated doses. The main question to answer is:\n\nIs there a significant effect on the combined use of TENS and IE on peripheral hemodynamic parameters in patients with resistant hypertension? Total sample will be 50 patients from both sexes\n\nI will compare between two groups:\n\nExperimental group (15 men, 10 women) will take: medication plus IE and TENS Control group (15 men, 10 women) will take: medication plus Conventional Physical Therapy Program",[87,88,26,89,90,91,92,93],"Resistant Hypertension","Hemodynamic Instability","Abdominal Obesity","Metabolic Syndrome","Hypertension (HTN)","Vascular Resistance","High Blood Pressure",[95,96,97,98,99,100,101,102],"Mean Arterial Pressure","Peripheral Hemodynamics","Physical Therapy","Long Term Hypertension","Resistant HTN","Systolic Blood Pressure (SBP)","Diastolic Blood Pressure (DBP)","Heart Rate Variability (HRV)","2026-01-28",{"date":105,"type":39},"2026-02-03",{"date":107,"type":19},"2026-01-15",{"date":109,"type":19},"2026-06-10",{"name":111,"class":46},"Mohamed Mohamed Ali Morgan"]